Eric Stoffregen

Eric Stoffregen

Lewis & Clark State College - Lewiston / United States
Natural Sciences / Molecular Biology & Genetics
AD Scientific Index ID: 1394098
-
person_outline Eric Stoffregen's MOST POPULAR ARTICLES
1-) In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain MutantsT O\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'Hare, DK Walters, EP Stoffregen, T Jia, PW Manley, J Mestan, ...Cancer research 65 (11), 4500-4505, 200512982005
2-) The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemiaRL Levine, M Loriaux, BJP Huntly, ML Loh, M Beran, E Stoffregen, ...Blood 106 (10), 3377-3379, 20054772005
3-) Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinibAS Corbin, PL Rosée, EP Stoffregen, BJ Druker, MW DeiningerBlood 101 (11), 4611-4614, 20034582003
4-) High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapySG Willis, T Lange, S Demehri, S Otto, L Crossman, D Niederwieser, ...Blood 106 (6), 2128-2137, 20054112005
5-) Activating alleles of JAK3 in acute megakaryoblastic leukemiaDK Walters, T Mercher, TL Gu, T O\'Hare, JW Tyner, M Loriaux, VL Goss, ...Cancer cell 10 (1), 65-75, 20063692006